Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Descriptor ID |
D006528
|
MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Liver Cell Carcinoma, Adult
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma
- Carcinoma, Liver Cell
- Carcinomas, Liver Cell
- Cell Carcinoma, Liver
- Cell Carcinomas, Liver
- Liver Cell Carcinomas
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in this website by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 2 | 6 |
1995 | 3 | 5 | 8 |
1996 | 3 | 0 | 3 |
1997 | 3 | 1 | 4 |
1998 | 4 | 2 | 6 |
1999 | 3 | 3 | 6 |
2000 | 9 | 5 | 14 |
2001 | 7 | 2 | 9 |
2002 | 15 | 8 | 23 |
2003 | 24 | 9 | 33 |
2004 | 28 | 6 | 34 |
2005 | 26 | 7 | 33 |
2006 | 26 | 5 | 31 |
2007 | 28 | 5 | 33 |
2008 | 33 | 7 | 40 |
2009 | 34 | 6 | 40 |
2010 | 37 | 9 | 46 |
2011 | 31 | 4 | 35 |
2012 | 23 | 1 | 24 |
2013 | 44 | 1 | 45 |
2014 | 33 | 4 | 37 |
2015 | 42 | 2 | 44 |
2016 | 42 | 3 | 45 |
2017 | 40 | 2 | 42 |
2018 | 41 | 7 | 48 |
2019 | 62 | 3 | 65 |
2020 | 67 | 1 | 68 |
2021 | 60 | 3 | 63 |
2022 | 69 | 1 | 70 |
2023 | 66 | 0 | 66 |
2024 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles.
-
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T?cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med. 2024 Mar 19; 5(3):101469.
-
Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States. Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb; 18(1-3):113-119.
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr; 9(4):310-322.
-
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma. Nat Commun. 2024 Feb 02; 15(1):1009.
-
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
-
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):159-169.
-
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135.
-
Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Pract Radiat Oncol. 2024 Mar-Apr; 14(2):134-145.
-
p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Res Commun. 2023 12 29; 3(12):2640-2652.
-
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance. Hepatol Commun. 2024 Jan 01; 8(1).